砒啶-2-硼酸二甲酯 | 136805-54-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 砒啶-2-硼酸二甲酯
• 中文别名: 吡啶-2-硼酸二甲酯
• 英文名称: dimethyl 2-pyridylboronate
• 英文别名: Dimethyl pyridin-2-ylboronate；dimethoxy(pyridin-2-yl)borane
• CAS: 136805-54-4
• 化学式: C₇H₁₀BNO₂
• mdl: MFCD03412109
• 分子量: 150.973
• InChiKey: ITSIDKYMJQVPQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.48
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933399090
• 储存条件：
  存储温度应低于-20°C。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Pyridine-2-Boronic Acid, Dimethyl Ester
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
This substance is not classified as dangerous according to Directive 67/548/EEC.
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Limited test data available for hazard assessment; handle with caution.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 150,97 g/mol
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
No special environmental precautions required.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
No special environmental precautions required.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  砒啶-2-硼酸二甲酯 在 potassium hydrogen bifluoride 作用下， 以 乙醚 、 正己烷 、 水 为溶剂， 反应 3.0h， 生成 (2-吡啶基)三氟硼酸钾
  参考文献：
  名称：

  钯催化的芳基三氟硼酸钾和杂芳基三氟硼酸钾的Suzuki-Miyaura交叉偶联反应。

  摘要：

  提出了对Suzuki-Miyaura交叉偶联反应中芳基三氟硼酸钾和杂芳基三氟硼酸钾的反应性的扩展研究。富芳基和电子富集的杂芳基三氟硼酸酯与芳基和活化的杂芳基溴化物的偶联在无配体条件下容易进行。当钝化的芳基和杂芳基三氟硼酸酯与芳基和杂芳基溴化物和氯化物偶联时，PdCl（2）（dppf）.CH（2）Cl（2）的低负载量（0.5-2％）有效催化反应。在任何一种条件下，反应通常可以在露天气氛中进行。

  DOI：

  10.1021/jo0342368
• 作为产物：
  描述：

  2-溴吡啶 、 硼酸三甲酯 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 生成 砒啶-2-硼酸二甲酯
  参考文献：
  名称：

  发光衰减的负活化能：特定溶剂化对双(2,2'-联吡啶)(3,5-二羧基-2,2'-联吡啶)氯化钌(II)发射特性的影响

  摘要：

  已经制备了一种新的混合配体聚吡啶基钌 (II) 复合物 [Ru(bpy)2L]Cl2，其中 bpy = 2,2'-联吡啶和 L = 3,5-二羧基-2,2'-联吡啶。配体L是非对称取代的2,2'-联吡啶，在其两个吡啶环中仅一个的3-和5-位具有两个亲水性羧酸酯基团。在乙腈中，金属配合物的光物理性质包括一个长寿命激发态（λem = 637 nm，τ = 846 ± 11 ns，φ = 0.046 at 295 K），其衰变涉及到更高能量配体场态的激活交叉（ Ea = 4170 ± 200 cm-1)。这种行为类似于对其他钌三（联吡啶）化合物所观察到的行为。相比之下，标题化合物在水溶液中显示出几种不寻常的光物理特性。这些包括强烈的红移发射 (λem = 685 nm)，具有短、pH 依赖性寿命，它被溶剂的激发态质子转移淬灭。分子的完全去质子化形式是主要的发射...

  DOI：

  10.1021/ja954015m

文献信息

• Aromatic interactions in the synthesis and conformation of two collapsible tetracationic cyclophanes
  作者：Milind D Sindkhedkar、Hormuzd R Mulla、Mark A Wurth、Arthur Cammers-Goodwin

  DOI：10.1016/s0040-4020(01)00162-4

  日期：2001.4

  The conformations of tetracationic paracyclophane and metacyclophane derivatives containing quaternary salts of para-2,2-diazaterphenyl were investigated. The molecules were synthesized as the bromide and hexafluorophosphate salts which allowed solubility in aqueous and organic solvents. Molecular mechanics led to the notion that these cyclophanes would populate collapsed and open conformations in water

  研究了含有对-2,2-二氮杂三联苯季盐的四阳离子对环烷和亚环烷衍生物的构象。这些分子以溴化物和六氟磷酸盐的形式合成，可以在水性和有机溶剂中溶解。分子力学导致了这样的想法，即这些环烷将在水中填充塌陷和开放的构象，而仅在有机溶剂中填充开放的构象子。VT NMR研究表明，开放的和折叠的构象异构体在NMR时标上没有交换。这些构象之一中的大的带正电荷的裂隙像分子级镊子那样在吡啶鎓环之间结合了平坦的阴离子。
• Synthesis and characterization of phenylpyridine derivative containing an imide functional group on an iridium (III) complex for solution-processable orange-phosphorescent organic light-emitting diodes
  作者：Jaeyoung Hwang、Kyoung Soo Yook、Jun Yeob Lee、Yun-Hi Kim

  DOI：10.1016/j.dyepig.2015.05.004

  日期：2015.10

  We report the synthesis and characterization of an orange-emitting iridium(III) complex, based on a phenylpyridine iridium derivative, bis[2-isopropyl-5-(pyridin-2-yl)isoindoline-1,3-dione]iridium(III) 2,2,6,6-tetramethyl-3,5-heptanedione ([(impy)2Ir(tmd)]), for orange-phosphorescent organic light-emitting diodes. The phenylpyridine derivative contained an imide functional group as the main ligand

  我们报告了基于苯基吡啶铱衍生物双[2-异丙基-5-（吡啶-2-基）异吲哚啉-1,3-二酮]铱（III）的橙色发射铱（III）配合物的合成和表征）2,2,6,6-四甲基-3,5-庚二酮（[（impy）2 Ir（tmd）]），用于橙色磷光有机发光二极管。苯基吡啶衍生物包含酰亚胺官能团作为主要配体，以及庞大的2,2,6,6-四甲基-3,5-庚二酮（tmd）作为辅助配体。易于通过旋涂处理的（impy）2 Ir（tmd）掺杂剂提供了6.1％的最大量子效率和16.3 cd A -1的最大电流效率。橙色OLED的FWHM为73nm，色坐标为（0.53，0.47）。
• 一种预防和治疗冠心病的药物及其应用
  申请人：哈尔滨医科大学

  公开号：CN106916143B

  公开（公告）日：2019-09-27

  本发明涉及一种具有优良的卵磷脂‑胆固醇乙酰基转移酶(即LCAT)激活效应，优选可逆LCAT激活效应的吲哚啉酮衍生物或其药学上可接受的盐。这类化合物包括式I所示化合物或其药学上可接受的盐：本发明化合物对LCAT具有优异的激动效应，并且对于HDL水平有显著的增加作用，因此适合用于预防和治疗心脑血管疾病如冠心病、动脉硬化等。
• Organometallic Iridium Complex Containing a Dianionic, Tridentate, Mixed Organic–Inorganic Ligand
  作者：Aaron J. Bloomfield、Adam J. Matula、Brandon Q. Mercado、Victor S. Batista、Robert H. Crabtree

  DOI：10.1021/acs.inorgchem.6b01218

  日期：2016.8.15

  A pentamethylcyclopentadienyl–iridium complex containing a tricyclic, dianionic, tridentate, scorpionate (facial binding), mixed organic–inorganic ligand was synthesized and characterized by single-crystal X-ray crystallography, as well as polynuclear NMR, UV–vis, and IR spectroscopies. The central cycle of the tridentate ligand consists of a modified boroxine in which two of the boron centers are

  合成了一种五甲基环戊二烯基-铱配合物，该配合物包含三环，双阴离子，三齿，蝎子（表面结合），混合的有机-无机配体，并通过单晶X射线晶体学，多核NMR，UV和IR光谱进行了表征。 。三齿配体的中心循环由修饰的环硼氧烷组成，其中两个硼中心是四面体阴离子硼酸酯。该络合物在25°C下可在水溶液中稳定水解> 9周，但可在12 s内与50 mM高碘酸钠溶液反应形成高碘酸盐驱动的析氧催化剂，其周转频率> 15 s –1。但是，催化剂在5分钟内几乎完全失活，平均循环次数约为。每个铱原子有2500个氧分子。在此时间范围内未观察到纳米颗粒，但在这些实验条件下催化剂活化后4小时内形成纳米颗粒。母体复合物是使用密度泛函理论建模的，该理论准确反映了复合物的几何形状，并表明了以铱和硼环为中心的轨道之间的显着相互作用。
• Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor
  申请人：Hynd George

  公开号：US20100093751A1

  公开（公告）日：2010-04-15

  Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, inter alia, respiratory diseases: wherein R 1 is fluoro, chloro, cyano or trifluoromethyl; R 2 is hydrogen, fluoro or chloro; R 3 is hydrogen, fluoro, chloro or trifluoromethyl; X is —CH 2 —, —S—, —S(═O)— or —S(═O) 2 —; one of Y and Y 1 is hydrogen and the other is —C(═O)R 4 , or —S(═O) 2 R 4 , or —CR 5 R 6 OR 7 or a heterocyclic group selected from furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, furazanyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,4-triazinyl and 1,3,5-triazinyl any of which may be optionally substituted; R 4 is an optionally substituted cyclic amino group having 5, 6 or 7 ring atoms which is linked to the carbonyl or sulfonyl through a ring nitrogen; R 5 and R 6 are independently hydrogen, (C 1 C 3 )alkyl, cyclopropyl, or R 5 and R 6 taken together with the carbon atom to which they are attached form a 3-6 membered cycloalkyl ring; and R 7 is optionally substituted (C 1 -C 6 )alkyl or (C 3 -C 6 )cycloalkyl,

  公式（I）的化合物是CRTH2配体，可用于治疗呼吸系统疾病，其中R1为氟、氯、氰或三氟甲基；R2为氢、氟或氯；R3为氢、氟、氯或三氟甲基；X为-CH2-、-S-、-S（═O）-或-S（═O）2-；Y和Y1中的一个为氢，另一个为-C（═O）R4、-S（═O）2R4、-CR5R6OR7或从呋喃基、噻吩基、吡咯基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异噻唑基、1,2,3-噁二唑基、1,2,4-噁二唑基、1,3,4-噁二唑基、1,2,5-噁二唑基、呋嗪基、1,2,3-三唑基、1,2,4-三唑基、1,2,3-噻二唑基、1,2,5-噻二唑基、1,3,4-噻二唑基、1,2,4-噻二唑基、四唑基、吡啶基、吡嗪基、嘧啶基、吡咯嗪基、1,2,4-三嗪基和1,3,5-三嗪基中选择的杂环基，其中任何一个均可选择性地被取代；R4是一个具有5、6或7个环原子的可选择性取代的环氨基基团，通过一个环氮原子与羰基或磺酰基相连；R5和R6独立地为氢、（C1-C3）烷基、环丙基，或R5和R6与它们附着的碳原子一起形成一个3-6个成员的环烷基环；R7是可选择性取代的（C1-C6）烷基或（C3-C6）环烷基。